Form 4: Director Michael Tarnoff Reports Equity Grants at AVITA

Director Michael Tarnoff disclosed the receipt of restricted stock units and stock options following shareholder approval.

Summary

• Director Michael E. Tarnoff received grants of restricted stock units (RSUs) and stock options for AVITA Medical, Inc. (RCEL).
• The grants consist of 26,250 RSUs and 19,063 stock options granted on August 6, 2025, and 22,214 RSUs and 16,133 stock options granted on January 20, 2026.
• All equity awards were subject to shareholder approval, which was officially obtained on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing reflecting standard director compensation practices rather than a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Formal shareholder approval obtained for all director equity grants.

Negatives

• None identified; this is a standard regulatory disclosure of director compensation.

Risks

• Value of equity grants is subject to market volatility of RCEL common stock.
• Vesting schedules create long-term dependency on company performance and retention.

Future Outlook

The equity grants are subject to time-based vesting criteria, with RSUs vesting over one to three years and options vesting in three equal annual installments.

Management Comments

• The grants were subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Industry Context

StockSavvy.ai notes that director equity compensation is a standard practice in the medical device sector to ensure board alignment with long-term shareholder value, particularly for growth-stage companies like AVITA Medical.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices in the U.S. healthcare sector.
• Granting options at the market price on the date of board approval aligns with SEC and Nasdaq compliance requirements.

Corporate Governance

Stakeholder Impact

• Shareholders: Dilution impact is minimal given the scale of grants relative to total outstanding shares.
• Director: Increased alignment with company performance.

Next Steps

• Vesting of RSUs and stock options according to the established schedules.
• Ongoing monitoring of director ownership levels.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, Director Compensation, Equity Grants, Insider Ownership